The Wood Laboratories, Inc., today declared results of the new analysis, demonstrating that Lexapro (escitalopram oxalate) provided greater reduction in estimation MADRS, using method LOCF and was better tolerated than Cymbalta (duloxetine), founded in percent patient, stopping processing because of disadvantage event, on processing patient with moderate in serious main depressive disorder.

Dr. (Read ‘Lexapro group terminated eight weeks’…)